Literature DB >> 2050181

Pharmacokinetics of ibuprofen in febrile children.

M C Nahata1, D E Durrell, D A Powell, N Gupta.   

Abstract

Ibuprofen may be an alternative to acetaminophen to control fever in children but little is known about its pharmacokinetics in pediatric patients. We studied 17 patients (age 3-10 yr) with fever; the most prevalent diagnoses were streptococcal pharyngitis and otitis media. Ibuprofen liquid was given as a single dose, 5 mg/kg (9 patients) or 10 mg/kg (8 patients). Multiple blood samples were collected over 8 hours and analyzed by HPLC. The maximum observed serum concentrations of ibuprofen ranged from 17-42 micrograms.ml-1 at 5 mg.kg-1 and 25-53 micrograms.ml-1 at 10 mg.kg-1 doses. Pharmacokinetics did not appear to be affected by ibuprofen dose. Mean tmax, oral clearance and elimination half life were 1.1 h, 1.2 ml.min-1.kg-1, and 1.6 h, respectively in patients at 5 mg.kg-1 doses; the corresponding values were 1.2 h, 1.4 ml.min-1.kg-1, and 1.6 h in those receiving 10 mg.kg-1 doses. There was no relationship between age and ibuprofen kinetics. No adverse effects occurred in any patients. These data suggest that ibuprofen pharmacokinetics may not be affected by dose between 5 and 10 mg/kg or age between 3 and 10 years.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2050181     DOI: 10.1007/bf00265858

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  2 in total

1.  Stereoselective disposition of ibuprofen enantiomers in synovial fluid.

Authors:  R O Day; K M Williams; G G Graham; E J Lee; R D Knihinicki; G D Champion
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

2.  Ibuprofen, acetaminophen, and placebo treatment of febrile children.

Authors:  P D Walson; G Galletta; N J Braden; L Alexander
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

  2 in total
  8 in total

Review 1.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

3.  Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen.

Authors:  I F Trocóniz; S Armenteros; M V Planelles; J Benítez; R Calvo; R Domínguez
Journal:  Clin Pharmacokinet       Date:  2000-06       Impact factor: 6.447

Review 4.  Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.

Authors:  Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker
Journal:  Paediatr Drugs       Date:  2022-09-02       Impact factor: 3.930

Review 5.  Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months.

Authors:  Victoria C Ziesenitz; Andreas Zutter; Thomas O Erb; Johannes N van den Anker
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

6.  Pharmacokinetics of intravenous and rectal ketoprofen in young children.

Authors:  Hannu Kokki; Marko Karvinen; Pekka Suhonen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

8.  Population pharmacokinetics of high dose ibuprofen in cystic fibrosis.

Authors:  I Arranz; A Martín-Suárez; J M Lanao; F Mora; C Vázquez; A Escribano; M Juste; J Mercader; E Ripoll
Journal:  Arch Dis Child       Date:  2003-12       Impact factor: 3.791

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.